Abstract Metastasis remains a major clinical problem in breast cancer. One family of genes previously linked with metastasis is the metastasis tumor-associated (MTA) family, with members MTA1 enhancing and MTA3 inhibiting cancer metastasis. We have previously found that MTA2 enhances anchorage-independent growth in estrogen receptor a (ERa) breast cancers, and, in combination with other genes, performed as a predictive biomarker in ERapositive breast cancer. We therefore hypothesized that MTA2 enhances breast cancer progression. To test this, cell growth, soft-agar colony formation, migration, and in vivo metastasis were examined in MTA2-overexpressing and Vector control transfected ERa-negative breast cancer cells. Pathways regulating cell-cell interaction, adhesion, and signaling through the Rho pathway were also investigated. Effects of the inhibition of the Rho pathway using a Rho Kinase inhibitor were assessed in soft-agar colony formation and motility assays in MTA2-overexpressing cells. MTA2 expression was associated with poor prognostic markers, and levels of MTA2 were associated with increased risk of early recurrence in retrospective analyses. MTA2 overexpression was associated with enhanced metastasis, and pathways regulating cell-cell interactions in vitro and in vivo. Most critically, MTA2-enhanced motility could be blocked by inhibiting Rho pathway signaling. We present the novel finding that MTA2 defined a subset of ERa-negative patients with a particularly poor outcome.
Introduction
The majority of breast cancer patients succumb to complications from distant metastases rather than the primary tumor [1] . Genes from many signaling pathways and regulatory networks have been implicated in metastasis formation including regulation of gene expression in the nucleus [2] and activation of cytoskeletal reorganization [3] [4] [5] [6] . Metastasis is a complex process involving invasion, anchorageindependent growth, survival, and growth at distant sites, where each step is rate limiting for metastasis [1] . Thus, there is a great clinical need for agents that can prevent or target the process of metastatic dissemination and formation.
The metastasis tumor-associated (MTA) family of proteins has been implicated in the metastatic process [7] [8] [9] [10] [11] .
MTA's are members of the nucleosome remodeling and histone deacetylation (NuRD) complex directing associated histone deacetylase (HDAC) to both histone and non-histone proteins, thus regulating chromatin condensation and protein function [7] [8] [9] [10] [11] [12] [13] . The MTA family comprises three genes MTA1, MTA2, and MTA3. Though MTA proteins are each members of the NuRD complex, they appear to mediate distinct cellular functions and to play different roles in the metastatic process [7, 9, 10] .
MTA1 was identified by cDNA screening of metastatic versus non-metastatic rat adenocarcinoma [14, 15] , and has been linked with metastasis in several cancer types [10] . Conversely, MTA3 is a repressor of snail [16] and is lost in the polyoma virus middle-T mammary oncogene model of mammary cancer, while MTA1 and MTA2 expression is retained [11] . MTA2 is critical for twist-mediated enhancement of migration of mouse 4T1 mammary tumors [13] , and overexpression of MTA2 in ERa-positive breast cancer cells resulted in an estrogen-independent phenotype with enhanced anchorage-independent growth [12] , a phenotype associated with metastasis. Thus, we hypothesize that MTA2 may have a role in metastasis in breast cancer.
Materials and methods

Plasmids and chemicals
The MTA2 plasmid (a kind gift from Wei Gu, Columbia University, New York, NY, USA) [12] and the YFP-tagged Rho GDIa plasmid have been previously described [17] . Fasudil and H-1152 were obtained from Tocris Biosciences (Ellisville, MO, USA) and suspended in H 2 O.
Cell culture and stable transfection ERa-negative MDA-MB-231 cells were obtained from American Type Tissue Culture Collection (Manassas, VA, USA). Cells were maintained at 37°C in 5 % CO in minimal essential medium (MEM; Invitrogen, Carlsbad, CA, USA) supplemented with 5 % fetal bovine serum (FBS, GemCell, West Sacramento, CA, USA), 200 units/mL penicillin, 200 lg/mL streptomycin, and non-essential amino acids (Invitrogen). Stably transfected MTA2 and Rho GDIaoverexpressing cell lines were generated as previously described [12] . For maintaining stable cell lines 1 g/L geneticin (Invitrogen) and/or 200 lg/mL zeocin was added.
Immunoblot analysis
Cell extracts were prepared using RIPA buffer (5 mM Tris-HCl pH 8, 150 mM NaCl, 1 % NP-40, 0.5 % sodium deoxycholate, 0.1 % SDS), or MOPS buffer (25 mM Hepes pH 7.5, 150 mM NaCl, 1 % igepal ca-630, 10 % glycerol, 25 mM NaF, 10 mM MgCl 2 , 1 mM EDTA, 10 mg/mL each of leupeptin and aprotinin) both supplemented with protease inhibitor cocktail III and phosphatase inhibitor cocktail I/II (Calbiochem, Darmstadt, Germany). Cell lysates were resolved by SDS-PAGE and assayed as previously described [12] . Membranes were probed with anti-MTA2 (Sigma, St. Louis, MO, USA), anti-Rho GDIa (Santa Cruz Biotechnology, Santa Cruz, CA, USA), or antiRhoC (Cell Signaling Technology, Beverly, MA, USA). Antibodies to GAPDH (Santa Cruz Biotechnology) or p190 (BD Biosciences) were used as loading controls.
Cell growth assays
Cells were cultured then treated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma) for 2 h at the specified time points. The resulting reaction was suspended in dimethyl sulfoxide and absorbance was measured at 550 and 655 nm.
Soft-agar colony formation assay
Soft-agar assays were performed as previously described [12] with some modifications. Briefly, six wells were coated with 2 mL pre-warmed (50°C) 0.7 % SeaPlaque agarose (FMC, Rockland, ME, USA) and solidified at 4°C for 1 h. Cells were suspended in 4 mL of pre-warmed (37°C) 0.35 % SeaPlaque agarose and plated at a density of 5,000 cells/well. Plates were cooled for 2 h at 4°C and then transferred to a 37°C humidified incubator. After 3 weeks, colonies were quantified using a GelCount colony counter (Oxford Optronix, Oxford, UK) following the manufacturer's instructions.
Wound-healing assays
Cells were seeded onto six-well plates at a density of 250,000 cells per well and allowed to grow to confluence. Cell layers were washed two times with MEM, scrapped using a pipette tip, and washed two additional times with MEM. Growth medium (supplemented with 10 lM H-1152, 100 lM Fasudil, 200 lM Fasudil, or H 2 O) was then placed on the cells and images were taken at times 0 and 24 h. Wound width was measured in pixels using ImageJ [18] .
Tumor xenograft experiments
Cells were cultured to 80 % confluence and harvested using Versene (Invitrogen). Cells were then injected into the number four mammary fat pad of athymic-nude female mice at a density of five million cells in 200 lL of 50 % Matrigel (BD Biosciences, San Jose, CA, USA) and 50 % growth medium (v/v). Tumors were allowed to grow to a volume of approximately 1,000 mm 3 after which the primary tumors were removed. Mice were then observed for the formation of distant metastases, after which, the mice were sacrificed and tissues processed for pathological evaluation. All immunohistochemistry was performed by the Lester and Sue Smith Breast Center Pathology Core facility at Baylor College of Medicine. Thin (5 lm) sections were stained with hematoxylin and eosin to detect metastases. Animals were housed and maintained in accordance with the animal care regulations of Baylor College of Medicine. All of the animal experiments were approved by the Baylor College of Medicine Institutional Animal Care and Use Committee pursuant to NIH guidelines.
Rho activity assays
Rho activity assays were performed as previously described [17] . Briefly, cells were cultured to 80 % confluence and harvested in RIPA buffer at 4°C. Lysates were clarified by centrifugation at maximum speed in a microcentrifuge for 5 min. Lysates were then incubated with rhotekin-bound beads for 2 h. The bead/lysate slurry was then washed three times with RIPA buffer, suspended in protein loading buffer, boiled, and subjected to immunoblot analysis.
Gene expression array hybridization RNA was extracted as previously described [19] . Briefly, Affymetrix (Santa Clara, CA, USA) gene expression array analysis was performed by collecting RNA from cells using the RNeasy Mini Kit from Qiagen (Valencia, CA, USA). RNA was processed to generate labeled-cRNA which was hybridized onto Affymetrix GeneChip human genome U133 plus 2.0 arrays using manufacturer-recommended procedures for hybridization, washing, and staining with streptavidin-phycoerythrin. GeneChips were scanned, and feature quantitation was done using Affymetrix protocols.
Statistical analysis
Oncomine [20] analysis was performed using the Oncomine tool (http://www.oncomine.org).
For gene expression analysis of cell lines, data were normalized and differential gene expression was assessed using the implementation of the Limma [21] and RMA [22] in Red-R [23] . Differentially expressed genes were filtered using a false discovery rate of 0.1.
For retrospective ERa-negative clinical gene expression analysis, data previously published by Wang et al. [24] (GSE2034) and Sabatier et al. [25] (GSE21653) were downloaded from gene expression omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo) [26] . Samples classified as being ERa-negative were used for all analyses. Both of these datasets were analyzed separately.
To assess genes that correlated with MTA2 expression genes were filtered to select those with variability greater than the 50 percentile of inter quartile range and compared with the MTA2 signal. Significantly correlated genes were submitted to DAVID [27] for pathway analysis.
For evaluation of MTA2 as a prognostic marker in the Sabatier et al. dataset, samples were classified as MTA2-high if they expressed MTA2 above the 75 percentile and MTA2-low if at or below the 75 percentile. For evaluating MTA2 and Rho GDIa together as a prognostic marker, the Wang et al. dataset was used and patients were classified as MTA2-high if above the 25 percentile of expression of MTA2 and Rho GDIa-low if less than the 75 percentile of expression for Rho GDIa. Cox proportional hazards models were calculated using the Survival [28] package in R [29] .
Other statistical analyses were applied to experimental data where appropriate. Cell growth assays were analyzed using linear models. Colony forming, Rho activity assays, and wound-healing assays were analyzed using ANOVA.
All statistical analyses were performed in the statistical programming language R [29] or Red-R [23] .
Results
MTA2 expression is associated with poor outcomes in ERa-negative patients
We hypothesized that MTA2 expression may be linked with metastatic spread in breast cancer. We searched for clinical features associated with MTA2 expression using Oncomine [20] . We found high MTA2 levels to be associated with poorer differentiation, greater clinical stage, higher clinical grade, and ERa-negative status (Table 1) , all features associated with poor outcomes [30, 31] . These data indicate that MTA2 is more highly expressed in breast cancers that have worse outcomes or have formed distant metastases. We extended these analyses by investigating the role of MTA2 on disease free survival using a dataset previously published by Sabatier et al. [25] . As MTA2 was associated with ERa-negative status, we limited our study to ERanegative tumors. Based on the Oncomine analyses, we focused on patients with higher level expression of MTA2, thus we pre-selected the 75 percentile of MTA2 expression to represent high expression of MTA2. Over the entire length of follow-up, we observed a trend to poorer recurrence-free survival in the MTA2-high group ( Fig. 1 ; p \ 0.08). Analysis of the survival curves indicated a violation of the assumption of proportional hazards (p \ 0.05) with an inflection point at 24 months (data not shown), indicating that the risk of recurrence between the MTA2-high and MTA2-low populations changes after 24 months. We had found that MTA2 was higher in Stage IV tumors, indicating that tumors with high levels of MTA2 may quickly develop clinically detectable metastases. We censored the survival data to 24 months and found that MTA2-high patients showed significantly poorer recurrence-free survival up to 24 months ( Fig. 1 ; p \ 0.006). These data indicate that MTA2 is associated with early recurrence in ERa-negative breast cancers.
MTA2 overexpression enhances anchorageindependent growth and metastasis After finding that MTA2 was associated with early metastasis in retrospective studies, we sought to verify these findings in ERa-negative breast cancer cell lines. We engineered the ERa-negative, metastatic, breast cancer cell line, MDA-MB-231, to overexpress MTA2 (designated MTA2.2 and MTA2.3) or control (designated Vector). Based on analysis of MTA2 mRNA expression, (published by Neve et al. [32] ). MDA-MB-231 cells have intermediate levels of MTA2 expression relative to other breast cancer cell lines (data not shown). Overexpression of MTA2 was validated using immunoblot assay (Fig. 2a) . The MTA2.2 and MTA2.3 clones consistently showed between 1.5-and 2-fold the level of MTA2 protein relative to Vector cells. We observed no difference (p = 0.998) in growth using MTT growth assays between the Vector control and MTA2.2 and MTA2.3 cells (Fig. 2b) . These data indicate that MTA2 overexpression did not affect cell growth.
The ability for cancer cells to migrate and survive in the circulation is required for metastasis dissemination [1] . We used soft-agar growth assays to mimic growth and survival in an anchorage-independent environment, and woundhealing assays to assess motility. We found that MTA2.3 and MTA2.2 cells demonstrated enhanced soft-agar growth compared to Vector by 5-to 15-fold, respectively (Fig. 2c , Vector v. MTA2.2; p = 6.3E-4, Vector v. MTA2.3; p = 7.8E-4). Additionally, these clones also demonstrated a 1.5-to 2-fold increase, respectively, in migration speed relative to Vector cells (Fig. 2d, Vector Values were normalized to the first reading for each group. c MTA2-overexpression increases anchorageindependent growth in MDA-MB-231 cells. Soft-agar colony formation assay of Vector control and MTA2-overexpressing cells, values were normalized to the Vector group. Cells were seeded into soft-agar and allowed to form colonies for 3 weeks after which colonies were counted using the GelCount system. d MTA2-overexpression increases motility of MDA-MB-231 cells. Cells were seeded into wells and wounded with the tip of a pipette. Images were taken at time points zero and 24 h and distance migrated was calculated in pixels from the images. e MTA2-overexpression does not increase tumor xenograft growth. MDA-MB-231 cells expressing either Vector control or MTA2 were grown as tumor xenografts in the mammary fat pad of female athymic-nude mice. Growth rates of tumors from Vector and MTA2-overexpressing cells, tumor volumes were measured twice weekly. f-k MTA2-overexpression enhances metastasis of MDA-MB-231 cells. Mouse lung (f-i) or skin (j, k) from mice receiving Vector control cells (f, g) or MTA2-overexpressing cells (h-k) was stained using IHC. *p \ 0.05, exact p values are indicated in the text. Error bars represent standard error of the mean. M metastasis. Scale bar (f, h, j), 500 lM. Scale bar (g, i, k), 50 lM ERa-negative breast cancer cells, consistent with a prometastatic phenotype. These data are consistent with previous observations in ERa-positive T47D cells [12] .
We next hypothesized that MTA2 could directly enhance metastasis in vivo. We injected MTA2.2 or Vector control cells into the number four mammary fat pads of female athymic-nude mice, and allowed the cells to form primary tumor xenografts. Primary xenografts developed in 100 % of the mice with both cell lines. Similar to growth in culture, the growth rate of the primary tumors was equivalent between the two groups ( Fig. 2e ; p [ 0.08, n = 10 mice per group). Thus, MTA2 overexpression did not significantly enhance primary tumor formation or growth. We allowed primary tumors to grow to 1,000 mm 3 in volume, at which point the primary tumor was surgically removed. The mice were monitored for the formation of distant metastases at this point. The Vector control did not form metastasis during the experimental time of 6 weeks (Fig. 2f, g ). However, within 2 weeks of surgery, large metastatic lesions were observed in MTA2.2-injected mice in multiple organs (Figs. 2h-k) . Thus, MTA2 overexpression in MDA-MB-231 cells enhanced their ability to form systemic and spontaneous metastases.
MTA2 increases expression of cytoskeletal remodeling genes
MTA2 is a component of the NuRD complex [7, 8, 10, 11, 13] , an essential regulator of gene expression. We hypothesized that MTA2 overexpression could exert a substantial impact on global gene regulation, potentially by activating a concerted metastatic program in breast cancer. To address this, we used Affymetrix microarray expression profiling to determine which cellular pathways were altered coincident with MTA2 overexpression. We found that 8189 probes were differentially expressed between the MTA2.2 and the Vector cell lines (FDR \ 0.1; n = 3 per group; Supplemental Table 1 ). We used DAVID [27] to identify cellular signaling pathways that were significantly enriched in genes regulated by MTA2. We found that many pathways differentially regulated between Vector and MTA2-overexpressing cells were involved in interactions between cells and the extracellular matrix (Table 2) . These pathways are known to be essential for tumor motility and metastasis [33] .
We next sought to confirm our observations of MTA2-induced gene expression changes in clinical breast cancer samples. We used data from the Sabatier et al. [25] and the Wang et al. [24] datasets to identify genes significantly correlated in expression with MTA2 in ERa-negative samples. We identified 12,527 probes (Supplemental Table 2 ) in the Sabatier et al. dataset and 382 probes (Supplemental Table 3 ) in the Wang et al. dataset to be correlated with MTA2 at p \ 0.01. The combined cell line and clinical data revealed several overlapping pathways (Table 2) . Changes in gene expression in the Rho pathway, such as RhoA-C, focal adhesion kinase, and Rho Kinase (ROCK), were significantly correlated with MTA2 expression. These data demonstrate that MTA2 overexpression activated a transcriptional profile that may induce a motile and metastatic phenotype, potentially through Rho pathway activation.
MTA2 overexpression increased activation of the Rho pathway
Signaling through the Rho pathway is essential for cell motility [34] [35] [36] . Increased activation of the Rho pathway has been associated with increased metastasis [37] . We previously reported that Rho GDIa, a negative regulator of the Rho pathway, downregulates the expression of MTA2 in ERa-positive cells [17] . Therefore, we performed immunoblot analysis to compare the levels of Rho GDIa in Vector, MTA2.2, and MTA2.3 cells. We found that endogenous expression of Rho GDIa was decreased in MTA2-overexpressing cells relative to Vector control cells (Fig. 3a) . We also found that the levels of Rho GDIa were lower in MTA2-overexpressing T47D cell lines compared with control. Knockdown of MTA2 in MDAMB321 cells using two
independent siRNA constructs resulted in increased expression of Rho GDIa (Fig. 3b) . These findings further reinforce the hypothesis that MTA2 and Rho GDIa form a regulatory signature, as we have previously suggested [17] .
To determine if the Rho pathway was indeed activated in MTA2-overexpressing cells, we performed Rho activity assays. We found that levels of GTP-bound (active) RhoC were increased in MTA2.2 and MTA2.3 by approximately 1.75-fold compared with Vector control cells ( Fig. 3c ; Vector v. MTA2.2; p = 0.046; Vector v. MTA2.3; p = 0.032). These data confirm our gene expression data indicating that MTA2 expression promoted Rho/cytoskeletal remodeling pathway activation.
To further confirm that the mechanism of MTA2 enhanced anchorage-independent growth was via Rho pathway activation, we overexpred a yellow fluorescent protein (YFP)-tagged Rho GDIa in MTA2.2 cells to inhibit the Rho pathway. We used immunoblot analysis to examine the expression of MTA2 and Rho GDIa in these cells (Fig. 3d) . Surprisingly, MTA2 protein levels were decreased, while endogenous Rho GDIa protein levels were increased in YFP-Rho GDIa cells. These data reinforce our previous observations that Rho GDIa and MTA2 are inversely regulated [17] .
We then subjected the YFP-Rho GDIa-overexpressing cells to soft-agar growth assays. We found that Rho GDIaoverexpression reduced the ability to form colonies in softagar relative to control ( Fig. 3e ; MTA2-Vector ? Rho GDIa-Vector v. MTA2.2 ? Rho GDIa-Vector; p = 6.3E-4, MTA2.2 ? Rho GDIa-Vector v. MTA2.2 ? Rho GDIa-YFP; p = 0.0021). These data lead us to conclude that MTA2 enhanced metastasis in breast cancer cells by activating the Rho/cytoskeletal remodeling pathway at multiple key signaling nodes including Rho activation and downregulation of Rho GDIa.
We next hypothesized that blocking the Rho pathway by inhibiting ROCK, could inhibit anchorage-independent growth and motility in MTA2-overexpressing cells. We performed soft-agar colony formation assays and woundhealing assays with the addition of H-1152, a potent ROCK inhibitor. We found that H-1152 inhibited soft-agar colony formation ( Fig. 3f ; Vector v. MTA2.2; p = 0.037, Vector v. MTA2.3; p = 0.016) and wound healing ( Fig. 3g ; Vector v. MTA2.2; p = 0.0089, Vector v. MTA2.3; p \ 1.8E-15) in both MTA2.2 and MTA2.3 cells. We also used a second, less specific, yet clinically tested, ROCK inhibitor, Fasudil [38, 39] and found that Fasudil was able to block motility of MTA2-overexpressing cells (Fig. 3g, Vector [40] , and these data indicate that ROCK function may be regulated by MTA2 levels. These findings support the model that the effects of MTA2 on cytoskeletal organization are dependent on activation of the Rho/ROCK pathway.
MTA2 and Rho GDIa form a prognostic signature in ERa-negative breast cancer To determine if MTA2 and Rho GDIa levels in combination form a prognostic signature in ERa-negative breast tumors, we examined these two factors in the ERa-negative subset of the Wang et al. [24] dataset. The Wang et al. dataset contains only lymph-node-negative tumor samples, which have better outcomes compared with lymph-node-positive samples [41] [42] [43] . While MTA2 alone was not prognostic in the Wang et al. dataset (data not shown), MTA2 expression in combination with Rho GDIa expression (MTA2-high/Rho GDIa-low versus all others) formed a signature that was prognostic for early recurrence at 24 months as in the Sabatier et al. dataset (Fig. 4 ; p = 0.018, p = 0.62 overall). These data indicate that a combination of MTA2 and Rho GDIa is required to predict outcome in lymph-node-negative breast cancer populations.
Discussion
We demonstrated that MTA2 is a metastasis enhancer in ERa-negative MDA-MB-231 breast cancer cells. These Fig. 4 MTA2 and Rho GDIa collaborate to enhance rapid metastasis in ERa-negative breast cancer. A gene signature was constructed using MTA2 and Rho GDIa. Patients from the Wang et al. [24] dataset were classified as MTA2-high and Rho GDIa-low showed significantly more recurrence events when data were censored to 24 months compared with all other patients (p = 0.018). No significant difference in outcomes was detected when the entire dataset was evaluated (p = 0.62) results are consistent with those reported for MTA1 overexpression [9] . However, MTA1 action was dependent on HIF1a [9] , where MTA2 appears operate through Rho signaling activation. We found that MTA2 is prognostic for cancer recurrence in two previously published ER-negative cohorts, as well as being associated with clinical determinants of poor outcomes. While we had previously demonstrated the prognostic value of MTA2 and Rho GDIa in ERa-positive breast cancer [17] , this is the first report to demonstrate their significance in ERa-negative tumors. This novel finding indicates that the effects of MTA2 on metastasis may be independent of its effects on hormonal resistance.
We found that MTA2 regulates the expression of many regulators of Rho signaling, potentially via NuRD activity. The effects of MTA2 are critically linked with Rho pathway activity, as inhibitors (Rho GDIa-add-back, Fasudil, or H-1152) could block the enhanced MTA2-associated motility and anchorage-independent growth phenotypes.
Metastases can form within 20 weeks after injection of parental MDA-MB-231 cell lines [44] . However, in MTA2-overexpressing models, metastases appeared within 6 weeks of initial tumor formation. In clinical data, MTA2 was increased in expression in patients presenting with Stage IV breast cancer [45] and was associated with earlier clinical metastases either alone or in combination with Rho GDIa [24, 25] . It is thought that breast cancer metastases arise from disseminated cells present at the time of surgery to remove the primary tumor which may remain undetectable for years [46] . While we have demonstrated that MTA2 can enhance the motile and anchorage-independent growth phenotypes of ERa-negative breast cancer cells, our in vivo and clinical data indicate that MTA2 may enhance colonization or growth at the distant site as well.
Our results demonstrate a complex regulatory relationship between MTA2 and Rho GDIa. Rho GDIa was also reported to participate in a feed-forward regulatory loop via c-jun kinase [47] , similar to our findings. Further studies are warranted to better understand the highly dynamic regulation of the Rho pathway influenced by MTA2 overexpression.
Our studies have identified two targetable pathways in breast cancer progression. MTA2 is known to regulate gene expression as a member of the NuRD complex [7] [8] [9] [10] [11] [12] [13] . HDAC inhibitors are being tested in clinical trials of metastatic cancer and have shown preclinical success in cell line models [48] . Fasudil has been approved for the treatment of cerebral vasospasm in Japan and has been studied in models of breast cancer metastasis with success [38] . While studies of the effects of Fasudil clinically are ongoing, our data raise the possibility that ROCK inhibitors could be effective breast cancer agents, particularly in those patients that overexpress MTA2.
